We are live on ! Find out more

PMI

Picard Medical

PMI

Market cap $10.8M

4.61 USD

-0.01

0.22%

At close Updated Sep 28, 4:00 PM EDT

Pre-market

After hours

4.60

-0.01

0.22%

1 day

-0.22%

5 days

18.51%

1 month

-47.61%

3 months

-40.9%

6 months

-91.46%

Year to date

-94.93%

1 year

-98.94%

5 years

-97.99%

10 years

-97.99%

About: Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing the SynCardia TAH, an implantable total artificial heart system. The company is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including the SynCardia TAH, which is designed to assume the full function of a failed human heart in patients suffering from advanced heart failure. The SynCardia TAH replaces both the left and right ventricles as well as all four heart valves.

Employees: 75

Healthcare Medical Instruments & Supplies

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Kuehn Law Encourages Investors of Picard Medical Inc. to Contact Law Firm

NEW YORK, Sept. 9, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Picard Medical Inc. (NYSE AMERICAN: PMI) breached their fiduciary duties to shareholders.

Kuehn Law Encourages Investors of Picard Medical Inc. to Contact Law Firm

PICARD MEDICAL INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Picard Medical, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Picard (PMI) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in Picard between September 2, 2025, and October 31, 2025 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at [email protected] or by telephone at (212) 355-4648.

PICARD MEDICAL INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Picard Medical, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Picard Medical Reports Second Quarter 2026 Financial Results

- Revenue Increases 39% and Net Loss Decreases 16%- Year-to-Date Revenue Increases 50%, with ~$0.9 Million in Gross Profit TUCSON, Ariz., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard Medical” or the “Company”), parent company of SynCardia Systems, LLC (“SynCardia”), maker of the world's first and only total artificial heart approved by both the U.S. FDA and Health Canada, today reported financial results for the second quarter ended June 30, 2026.

Picard Medical Reports Second Quarter 2026 Financial Results

Picard Medical / SynCardia Presents Emperor Total Artificial Heart Architecture for the First Time at IEEE EMBC 2026

–First public scientific presentation provides the biomedical engineering community with its first detailed view of the next-generation total artificial heart platform– –First public scientific presentation provides the biomedical engineering community with its first detailed view of the next-generation total artificial heart platform–

Picard Medical / SynCardia Presents Emperor Total Artificial Heart Architecture for the First Time at IEEE EMBC 2026

Picard Medical / SynCardia to Present Next-Generation Emperor Total Artificial Heart Technology at IEEE EMBC 2026

-First scientific presentation of the Emperor Drive System architecture to the biomedical engineering community- TUCSON, Ariz., July 27, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) ("Picard" or the "Company"), parent company of SynCardia Systems LLC, maker of the world's first and only total artificial heart approved by the U.S. Food and Drug Administration (FDA) and Health Canada, today announced that Taha Hasekioglu, Director, Office of the COO & Emperor Program Lead, will present new engineering insights into the Company's next-generation Emperor Total Artificial Heart (Emperor TAH) system during the 48th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC 2026), taking place July 26–30, 2026, in Toronto, Canada.

Picard Medical / SynCardia to Present Next-Generation Emperor Total Artificial Heart Technology at IEEE EMBC 2026

Picard Medical Receives NYSE American Acceptance of Compliance Plan

-Company continues advancing long-term growth strategy under accepted compliance plan- -Company continues advancing long-term growth strategy under accepted compliance plan-

Picard Medical Receives NYSE American Acceptance of Compliance Plan

Picard Medical Announces Reverse Stock Split Following Stockholder Approval to Support Continued NYSE American Listing Compliance

-Reverse stock split to support continued compliance with NYSE American continued listing standards- TUCSON, Ariz., July 21, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the "Company" or "Picard Medical"), parent company of SynCardia Systems LLC, maker of the world's first and only total artificial heart approved by both the U.S. Food and Drug Administration ("FDA") and Health Canada, today announced that its Board of Directors has approved the implementation of a 1-for-50 reverse stock split of the Company's issued and outstanding common stock (the “Reverse Stock Split”).

Picard Medical Announces Reverse Stock Split Following Stockholder Approval to Support Continued NYSE American Listing Compliance

Picard Medical, Inc. (PMI) Shareholder/Analyst Call Prepared Remarks Transcript

Picard Medical, Inc. (PMI) Shareholder/Analyst Call Prepared Remarks Transcript

Picard Medical, Inc. (PMI) Shareholder/Analyst Call Prepared Remarks Transcript

Artificial Organs Publishes Independent Commentary on Picard Medical and SynCardia's Emperor Total Artificial Heart Program

Peer-reviewed journal's News section highlights the Company's continued progress toward a fully implantable total artificial heart Peer-reviewed journal's News section highlights the Company's continued progress toward a fully implantable total artificial heart

Artificial Organs Publishes Independent Commentary on Picard Medical and SynCardia's Emperor Total Artificial Heart Program

Picard Medical / SynCardia Releases Annual Stockholder Presentation Ahead of 2026 Annual Meeting

Presentation Highlights Business Progress, Product Development Milestones, and Matters for Stockholder Consideration Presentation Highlights Business Progress, Product Development Milestones, and Matters for Stockholder Consideration

Picard Medical / SynCardia Releases Annual Stockholder Presentation Ahead of 2026 Annual Meeting

See News Rankings

Price charts implemented using Lightweight Charts™